Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MQSA Panel Urges “Relevant” Equipment Testing To Limit Facility Downtime

This article was originally published in The Gray Sheet

Executive Summary

FDA needs to identify a way to evaluate mammography equipment components that does not incapacitate testing facilities, according to the agency's National Mammography Quality Assurance Advisory Committee
Advertisement

Related Content

National Mammography Database Would Lessen Inspection Burden – Panel
National Mammography Database Would Lessen Inspection Burden – Panel
Mammography AEC Testing Standards Need Further Review, NEMA Contends
Mammography AEC Testing Standards Need Further Review, NEMA Contends
Mammography AEC Testing Vital Only For Clinically Used Modes – FDA
Mammography AEC Testing Vital Only For Clinically Used Modes – FDA
MQSA Reauthorization Bill Calls For IoM, GAO Mammography Studies
MQSA Reauthorization Bill Calls For IoM, GAO Mammography Studies
Advertisement
UsernamePublicRestriction

Register

MT017092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel